Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
P/B ratio for Ocuphire Pharma, Inc. (OCUP)
P/B ratio as of 2023: 1.30
According to Ocuphire Pharma, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.30. At the end of 2022 the company had a P/B ratio of 1.52.
P/B ratio history for Ocuphire Pharma, Inc. from 2005 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 1.30 |
| 2022 | 1.52 |
| 2021 | 2.49 |
| 2020 | -2.25 |
| 2019 | -0.72 |
| 2018 | 2.90 |
| 2017 | 3.30 |
| 2016 | 1.78 |
| 2015 | 3.50 |
| 2014 | 2226.14 |
| 2013 | 2494.43 |
| 2012 | 1516.07 |
| 2011 | 1585.26 |
| 2010 | 0.00 |
| 2009 | 2474.78 |
| 2008 | 8821.17 |
| 2007 | 8051.03 |
| 2006 | 9852.73 |
| 2005 | 0.00 |